Isoxazole Derivatives as Selective FXR Agonists
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective FXR modulators to treat and prevent various diseases, as existing small molecule FXR modulators have limitations in efficacy and specificity.
Innovation Solution
Development of isoxazole compounds containing an acylsulfonamide or sulfonylurea moiety, represented by specific chemical formulas, which act as selective FXR agonists or modulators, for use in pharmaceutical compositions to treat FXR-mediated diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing small molecule FXR modulators are used, then FXR modulation is achieved, but efficacy and specificity are limited
Solution Approach 1:
The patent modifies molecular parameters of FXR modulators by introducing specific structural features (isoxazole core, acylsulfonamide/sulfonylurea moieties, particular substituent patterns) to enhance both efficacy and specificity. The systematic variation of R1-R7 substituents and ring structures allows optimization of ligand-receptor binding properties.
Solution Approach 2:
The invention creates composite molecular structures combining multiple functional elements: isoxazole ring, acylsulfonamide or sulfonylurea moiety, and various aromatic/heteroaromatic substituents. This composite approach integrates different pharmacophoric elements to achieve superior FXR modulation compared to single-structure modulators.
2Adaptability or versatility
If FXR modulators are developed to treat multiple disease types, then therapeutic versatility is improved, but compound complexity increases
Solution Approach 1:
The patent designs FXR modulators with universal applicability across multiple disease indications (cardiovascular, liver, gastrointestinal, renal, and metabolic disorders) through a core structural framework that can be systematically modified. The isoxazole-based scaffold with variable substituents serves multiple therapeutic purposes while maintaining a consistent foundational structure.
Solution Approach 2:
The molecular structure is divided into distinct functional segments (R1-R7 substituents, core isoxazole, acylsulfonamide/sulfonylurea moiety) that can be independently optimized. This segmentation allows tailored modification for specific disease targets while preserving the core FXR-binding pharmacophore.
Data Source
AI summary
The present invention provides compounds of Formula I,pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.